Research and standardization in Alzheimer's trials: Reaching international consensus

Alzheimer's and Dementia

Volumn 9, Issue 2, 2013, Pages 160-168

  Carrillo, Maria C ^a   Rowe, Christopher C ^b   Szoeke, Cassandra ^c   Masters, Colin L ^d   Ames, David ^c,d   O'Meara, Tim ^e   Macaulay, S Lance ^e   Milner, Andrew ^f   Ellis, Kathryn A ^d   Maruff, Paul ^d   Rainey Smith, Stephanie R ^g   Martins, Ralph N ^g   Bain, Lisa J ^h   Head, Richard J ^e  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b AUSTIN HEALTH   (Australia)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CSIRO   (Australia)

^f Neurosciences Victoria   (Australia)

^g EDITH COWAN UNIVERSITY   (Australia)

^h Independent Science Writer   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Biomarkers; Cerebral spinal fluid; Clinical outcomes; Diagnosis; Early detection; Magnetic resonance imaging

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHY SCANNER; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; DIET; EARLY DIAGNOSIS; GOLD STANDARD; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; LONGITUDINAL STUDY; MEDICAL RESEARCH; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; STANDARDIZATION;

EID: 84875371210     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.10.006     Document Type: Note

References (53)

1. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
2. C.R. Jack Jr., M. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, M.C. Carrillo, and B. Thies Introduction to revised criteria for the diagnosis of Alzheimer's disease: National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 2011
3. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 2011
4. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 2011
5. J.C. Morris Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer Disease dementia Arch Neurol 2012
6. J.C. Morris, and D.J. Selkoe Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview Neurobiol Aging 32 2011 S1 S3
7. R.J. Bateman, P.S. Aisen, B. De Strooper, N.C. Fox, C.A. Lemere, and J.M. Ringman Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther 3 2011 1
8. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, and N. Ayutyanont Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 26 2011 321 329
9. A.G. Vlassenko, M.A. Mintun, C. Xiong, Y.I. Sheline, A.M. Goate, and T.L. Benzinger Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data Ann Neurol 70 2011 857 861
10. R.O. Roberts, Y.E. Geda, D.S. Knopman, R.H. Cha, V.S. Pankratz, and B.F. Boeve The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics Neuroepidemiology 30 2008 58 69
11. P. Scheltens, and K. Rockwood How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 7 2011 486 489
12. G.B. Frisoni, N.C. Fox, C.R. Jack Jr., P. Scheltens, and P.M. Thompson The clinical use of structural MRI in Alzheimer disease Nat Rev Neurol 6 2010 67 77
13. C. Cordonnier, and W.M. van der Flier Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 134 2011 335 344
14. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, and B.T. Hyman Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 7 2011 367 385
15. European Medicines Agency. Qualification opinion of low hippocampal volume (atrophy) by MRI for use in regulatory clinical trials in pre-dementia stage of Alzheimer's disease. Available at: < http://www.ema.europa.eu/docs/ en-GB/document-library/Regulatory-and-procedural-guideline/2011/10/WC500116264. pdf 11 >. Accessed April 2012.
16. G.B. Frisoni, and C.R. Jack Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use Alzheimers Dement 7 2011 171 174
17. C.R. Jack Jr., F. Barkhof, M.A. Bernstein, M. Cantillon, P.E. Cole, and C. Decarli Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease Alzheimers Dement 7 2011 474 485 e474
18. M. Boccardi, M. Bocchetta, L. Apostolova, J. Barnes, G. Bartzokis, and G. Corbetta Delphi consensus on landmarks for the manual segmentation of the hippocampus on MRI: preliminary results from the EADC-ADNI Harmonization Protocol Working Group (S04.003) Neurology 78 2012
19. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319
20. L. Yang, D. Rieves, and C. Ganley Brain amyloid imaging-FDA approval of florbetapir F18 injection N Engl J Med 367 2012 885 887
21. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 2011 275 283
22. H. Barthel, H.J. Gertz, S. Dresel, O. Peters, P. Bartenstein, and K. Buerger Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy control subjects: a multicentre phase 2 diagnostic study Lancet Neurol 10 2011 424 435
23. R. Vandenberghe, K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, and E. Triau 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 68 2010 319 329
24. A. Jureus, B.M. Swahn, J. Sandell, F. Jeppsson, A.E. Johnson, and P. Johnstrom Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand J Neurochem 114 2010 784 794
25. L. Mosconi, W.H. Tsui, K. Herholz, A. Pupi, A. Drzezga, and G. Lucignani Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias J Nucl Med 49 2008 390 398
26. A. Caroli, A. Prestia, K. Chen, N. Ayutyanont, S.M. Landau, and C.M. Madison Summary metrics to assess Alzheimer's disease-related hypometabolic pattern with FDG-PET: head-to-head comparison J Nucl Med 53 2012 592 600
27. J.H. Burdette, S. Minoshima, T. Vander Borght, D.E. Tran, and D.E. Kuhl Alzheimer disease: improved visual interpretation of PET images using three dimensional stereotaxic surface projections Radiology 198 1996 837 843
28. K.A. Johnson, N.C. Fox, R.A. Sperling, and W.E. Klunk Brain imaging in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006213
29. Y.I. Sheline, M.E. Raichle, A.Z. Snyder, J.C. Morris, D. Head, and S. Wang Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly Biol Psychiatry 67 2010 584 587
30. Y.I. Sheline, J.C. Morris, A.Z. Snyder, J.L. Price, Z. Yan, and G. D'Angelo APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42 J Neurosci 30 2010 17035 17040
31. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
32. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects Ann Neurol 65 2009 403 413
33. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
34. M. Isaac, S. Vamvakas, E. Abadie, B. Jonsson, C. Gispen, and L. Pani Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal fluid-related biomarkers for drugs affecting amyloid burden: regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials Eur Neuropsychopharmacol 21 2011 781 788
35. D.B. Henley, P.C. May, R.A. Dean, and E.R. Siemers Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease Expert Opin Pharmacother 10 2009 1657 1664
36. N. Mattsson, L. Rajendran, H. Zetterberg, M. Gustavsson, U. Andreasson, and M. Olsson BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system PLoS One 7 2012 e31084
37. K. Blennow Biomarkers in Alzheimer's disease drug development Nat Med 16 2010 1218 1222
38. T.S. Reijn, M.O. Rikkert, W.J. van Geel, D. de Jong, and M.M. Verbeek Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins Clin Chem 53 2007 859 865
39. N. Mattsson, H. Zetterberg, and K. Blennow Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease Int J Alzheimers Dis 2010
40. R. Zimmermann, N. Lelental, O. Ganslandt, J.M. Maler, J. Kornhuber, and P. Lewczuk Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics J Alzheimers Dis 25 2011 739 745
41. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395 e386
42. E. Portelius, R.A. Dean, M.K. Gustavsson, U. Andreasson, H. Zetterberg, and E. Siemers A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Res Ther 2 2010 7
43. A. Hye, S. Lynham, M. Thambisetty, M. Causevic, J. Campbell, and H.L. Byers Proteome-based plasma biomarkers for Alzheimer's disease Brain 129 2006 3042 3050
44. M. Thambisetty, A. Simmons, A. Hye, J. Campbell, E. Westman, and Y. Zhang Plasma biomarkers of brain atrophy in Alzheimer's disease PLoS One 6 2011 e28527
45. C.R. Jack Jr., P. Vemuri, H.J. Wiste, S.D. Weigand, T.G. Lesnick, and V. Lowe Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Arch Neurol 69 2012 856 867
46. L.E. Middleton, A. Mitnitski, N. Fallah, S.A. Kirkland, and K. Rockwood Changes in cognition and mortality in relation to exercise in late life: a population based study PLoS One 3 2008 e3124
47. J. Weuve, J.H. Kang, J.E. Manson, M.M. Breteler, J.H. Ware, and F. Grodstein Physical activity, including walking, and cognitive function in older women JAMA 292 2004 1454 1461
48. B.M. Brown, J.J. Peiffer, K. Taddei, J.K. Lui, S.M. Laws, and V.B. Gupta Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing Mol Psychiatry 2012
49. C. Feart, C. Samieri, V. Rondeau, H. Amieva, F. Portet, and J.F. Dartigues Adherence to a Mediterranean diet, cognitive decline, and risk of dementia JAMA 302 2009 638 648
50. N. Scarmeas, Y. Stern, M.X. Tang, R. Mayeux, and J.A. Luchsinger Mediterranean diet and risk for Alzheimer's disease Ann Neurol 59 2006 912 921
51. C.C. Tangney, M.J. Kwasny, H. Li, R.S. Wilson, D.A. Evans, and M.C. Morris Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population Am J Clin Nutr 93 2011 601 607
52. Global Alzheimer's Association Interactive Network, www.gaain.org. Accessed April 2012.
53. L.M. Refolo, H. Snyder, C. Liggins, L. Ryan, N. Silverberg, and S. Petanceska Common Alzheimer's research ontology: National Institute on Aging and Alzheimer's Association collaborative project Alzheimers Dement 8 2012